

VIVUS INC
Form 8-K
July 15, 2004

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

**FORM 8-K
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934**

Date of report (date of earliest event reported): **July 15, 2004**

VIVUS, INC
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

COMMISSION FILE NUMBER: 0 23490

DELAWARE
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION) **94 3136179**
(I.R.S. EMPLOYER
IDENTIFICATION NO.)

**1172 CASTRO STREET
MOUNTAIN VIEW, CA**
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES
94040
(ZIP CODE)

(650) 934 5200
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)

N/A
(FORMER NAME, FORMER ADDRESS AND FORMER FISCAL YEAR, IF CHANGED SINCE LAST REPORT)

Item 5. Other Events and Regulation FD Disclosure.

On July 14, 2004, the Registrant issued a press release announcing that data from a recently completed Phase 2 clinical trial demonstrated that ALISTA, our topical formulation of alprostadil for the treatment of female sexual arousal disorder (FSAD), significantly increased the percentage of satisfying sexual events in pre-menopausal women with FSAD when compared with placebo. The press release is attached as exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 7. Exhibits.

(c)

Exhibit

Number	Description
99.1	Press Release dated July 14, 2004.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: July 15, 2004

VIVUS, INC.

/s/ LARRY J. STRAUSS

Larry J. Strauss

Vice President and Chief Financial Officer

3

VIVUS, INC.

INDEX TO EXHIBITS

The following exhibits are filed herewith:

Exhibit	Description
99.1	Press Release dated July 14, 2004.

4
